S-RACMO signed a final agreement with Takara Bio concerning the transfer of Takara Bio’s GMP cell-processing contract business. The agreement, signed on 2 November 2026, was announced as a basic agreement.
S-RACMO, a joint venture between Sumitomo Pharma and Sumitomo Chemical, announced that it had signed a basic agreement with Takara Bio on 2 November 2026 as the final agreement concerning the transfer of the GMP cell-processing contract business.
The agreement concerns the transfer of the rights and obligations relating to the GMP cell-processing contract business. The article does not provide specific terms, amounts or other details.
S-RACMO announced that the agreement had been signed on the same date, with Takara Bio identified as the counterparty.
S-RACMO, a joint venture between Sumitomo Pharma and Sumitomo Chemical, explained that the transfer would maintain business continuity and the existing operating structure.